HASHEM EL-SERAG to Liver Cirrhosis
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Liver Cirrhosis.
Connection Strength
14.622
-
Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon. Aliment Pharmacol Ther. 2025 Apr; 61(7):1226-1237.
Score: 0.587
-
Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatol Commun. 2024 Nov 01; 8(11).
Score: 0.574
-
PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk. Clin Gastroenterol Hepatol. 2024 Sep; 22(9):1858-1866.e4.
Score: 0.557
-
An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients. Dig Dis Sci. 2024 Jul; 69(7):2430-2436.
Score: 0.557
-
Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. Gastroenterology. 2020 07; 159(1):376-377.
Score: 0.419
-
Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020 03; 71(3):808-819.
Score: 0.416
-
Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol. 2019 03; 114(3):530-532.
Score: 0.389
-
Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1886-1893.e5.
Score: 0.383
-
Ancestry and Risk of Hepatic Fibrosis and Inflammation in Patients With HCV Infection. Clin Gastroenterol Hepatol. 2019 08; 17(9):1912-1914.
Score: 0.379
-
Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018 12; 155(6):1828-1837.e2.
Score: 0.375
-
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 10; 153(4):996-1005.e1.
Score: 0.346
-
Trends in 30-Day and 1-Year Mortality Among Patients Hospitalized With Cirrhosis From 2004 to 2013. Am J Gastroenterol. 2017 Aug; 112(8):1287-1297.
Score: 0.345
-
?Ongoing alcohol consumptions counteracts the benefits of sustained virological response in patients with well compensated hepatitis C cirrhosis: an observational study. Ann Hepatol. 2017 Jan-Feb 2017; 16(1):16-20.
Score: 0.335
-
Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis. Hepatology. 2016 08; 64(2):569-81.
Score: 0.319
-
The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis. Gastroenterology. 2015 Dec; 149(7):1986-7.
Score: 0.308
-
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C. Clin Gastroenterol Hepatol. 2015 Aug; 13(8):1521-31.e3.
Score: 0.295
-
Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014 Sep; 109(9):1427-35.
Score: 0.283
-
HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014 Jul; 60(1):98-105.
Score: 0.280
-
A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014 May; 146(5):1249-55.e1.
Score: 0.273
-
Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):327-333.e1.
Score: 0.265
-
Dietary fructose intake and severity of liver disease in hepatitis C virus-infected patients. J Clin Gastroenterol. 2013 Jul; 47(6):545-52.
Score: 0.263
-
The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males. Aliment Pharmacol Ther. 2013 Jul; 38(1):28-37.
Score: 0.261
-
a-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it. Clin Gastroenterol Hepatol. 2013 Apr; 11(4):441-3.
Score: 0.255
-
The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs. Gastroenterology. 2012 Jul; 143(1):70-7.
Score: 0.241
-
Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology. 2012 Mar; 55(3):759-68.
Score: 0.236
-
Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010 Jul; 52(1):132-41.
Score: 0.213
-
The utility of evaluating low serum albumin gradient ascites in patients with cirrhosis. Am J Gastroenterol. 2009 Jun; 104(6):1401-5.
Score: 0.196
-
Management of the single liver nodule in a cirrhotic patient: a decision analysis model. J Clin Gastroenterol. 2005 Feb; 39(2):152-9.
Score: 0.147
-
The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol. 2005 Jan; 100(1):56-63.
Score: 0.146
-
Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med. 2004 Nov 22; 164(21):2349-54.
Score: 0.145
-
Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis. Gastroenterology. 2025 Mar; 168(3):556-567.e7.
Score: 0.144
-
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
Score: 0.144
-
HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology. 2025 Feb 01; 81(2):465-475.
Score: 0.140
-
The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol. 2003 Nov; 98(11):2535-42.
Score: 0.134
-
Bioimpedance analysis predicts the etiology of cirrhosis in a prospective cohort study. Hepatol Commun. 2023 10 01; 7(10).
Score: 0.133
-
Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
Score: 0.130
-
Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference. Clin Gastroenterol Hepatol. 2023 08; 21(9):2183-2192.
Score: 0.129
-
Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One. 2023; 18(2):e0282309.
Score: 0.128
-
Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
Score: 0.128
-
Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2023 02; 43(1):89-99.
Score: 0.125
-
Surveillance for hepatocellular carcinoma: does it work? Am J Gastroenterol. 2002 Oct; 97(10):2676-7.
Score: 0.125
-
Admixture Mapping in African Americans Identifies New Risk Loci for HCV-Related Cirrhosis. Clin Gastroenterol Hepatol. 2023 04; 21(4):1023-1030.e39.
Score: 0.122
-
GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology. 2022 03; 75(3):541-549.
Score: 0.118
-
Preparing for the NASH epidemic: A call to action. Metabolism. 2021 09; 122:154822.
Score: 0.115
-
Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol. 2001 Jul; 96(7):2206-10.
Score: 0.114
-
A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila). 2021 06; 14(6):667-674.
Score: 0.112
-
Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. JAMA Netw Open. 2020 11 02; 3(11):e2023780.
Score: 0.109
-
Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020 10; 72(4):1242-1252.
Score: 0.109
-
External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population. Dig Dis Sci. 2021 07; 66(7):2387-2393.
Score: 0.107
-
Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. Clin Gastroenterol Hepatol. 2021 07; 19(7):1443-1450.e6.
Score: 0.107
-
Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J Hepatol. 2020 12; 73(6):1425-1433.
Score: 0.106
-
Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. Dig Dis Sci. 2019 06; 64(6):1470-1477.
Score: 0.097
-
Implementation of a Population-Based Cirrhosis Identification and Management System. Clin Gastroenterol Hepatol. 2018 08; 16(8):1182-1186.e2.
Score: 0.092
-
Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis. Hepatology. 2018 07; 68(1):7-9.
Score: 0.092
-
Editorial: NAFLD-related hepatocellular carcinoma - increasing or not? With or without cirrhosis? Aliment Pharmacol Ther. 2018 02; 47(3):437-438.
Score: 0.090
-
Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications. Clin Gastroenterol Hepatol. 2018 10; 16(10):1677-1678.
Score: 0.090
-
Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol. 2018 01 04; 18(1):1.
Score: 0.090
-
Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017 11; 46(10):992-1000.
Score: 0.088
-
Hepatocellular carcinoma surveillance: The road ahead. Hepatology. 2017 03; 65(3):771-773.
Score: 0.084
-
Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers. Am J Gastroenterol. 2016 12; 111(12):1778-1787.
Score: 0.082
-
Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV. Dig Dis Sci. 2017 01; 62(1):76-83.
Score: 0.082
-
Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. J Hepatol. 2016 12; 65(6):1148-1154.
Score: 0.081
-
Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat. 2016 09; 23(9):687-96.
Score: 0.079
-
Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 2016 Mar; 43(5):621-30.
Score: 0.078
-
Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2014 Dec; 60(6):1871-8.
Score: 0.072
-
The quality of care provided to patients with varices in the department of Veterans Affairs. Am J Gastroenterol. 2014 Jul; 109(7):934-40.
Score: 0.070
-
WNT signaling pathway gene polymorphisms and risk of hepatic fibrosis and inflammation in HCV-infected patients. PLoS One. 2013; 8(12):e84407.
Score: 0.068
-
Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013 Nov; 52 Suppl 1:E139-47.
Score: 0.065
-
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012 May; 142(6):1264-1273.e1.
Score: 0.061
-
Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011 Jul; 60(7):992-7.
Score: 0.055
-
Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011 Jan 18; 154(2):85-93.
Score: 0.055
-
Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011 Apr; 140(4):1182-1188.e1.
Score: 0.055
-
Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010 Nov; 8(11):924-33; quiz e117.
Score: 0.054
-
The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010 Jul; 42 Suppl 3:S206-14.
Score: 0.053
-
An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):709-17.
Score: 0.052
-
The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther. 2008 Feb 01; 27(3):274-82.
Score: 0.044
-
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007 Jun; 132(7):2557-76.
Score: 0.043
-
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol. 2007 May; 102(5):1016-21.
Score: 0.042
-
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004 Feb; 126(2):460-8.
Score: 0.034
-
Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med. 2003 Apr 15; 138(8):627-33.
Score: 0.032
-
Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023 03; 78(3):493-500.
Score: 0.031
-
Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality. JAMA Netw Open. 2022 10 03; 5(10):e2234221.
Score: 0.031
-
Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection. Am J Gastroenterol. 2022 11 01; 117(11):1834-1844.
Score: 0.031
-
Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation. Clin Gastroenterol Hepatol. 2023 08; 21(9):2410-2412.e1.
Score: 0.031
-
Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2001 Feb; 5(1):87-107, vi.
Score: 0.028
-
Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2021 08; 19(8):1679-1687.
Score: 0.027
-
Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021 01; 19(1):61-71.e15.
Score: 0.026
-
Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. J Hepatol. 2019 04; 70(4):639-647.
Score: 0.024
-
Hepatitis C virus-related complications are increasing in women veterans: A national cohort study. J Viral Hepat. 2017 11; 24(11):955-965.
Score: 0.022
-
Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2017 02; 66(2):355-362.
Score: 0.021